Nima Farzan M.B.A. is the Pres, CEO & Director at Kinnate Biopharma.
As the Pres and CEO & Director of Kinnate Biopharma, the total compensation of Mr A at Kinnate Biopharma is $647,291. There are no executives at Kinnate Biopharma getting paid more.
Mr A is 45, he's been the Pres and CEO & Director of Kinnate Biopharma since . There are 2 older and 2 younger executives at Kinnate Biopharma. The oldest executive at Kinnate Biopharma Inc. is Dr. Richard Thomas Williams MBBS, Ph.D., 52, who is the Chief Medical Officer.
Nima's mailing address filed with the SEC is C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421.
Over the last 4 years, insiders at Kinnate Biopharma have traded over $0 worth of Kinnate Biopharma stock and bought 12,223,600 units worth $79,803,534 . The most active insiders traders include Carl L Gordon, Advisors Llc Orbi Med Capit..., and Helen Sabzevari. On average, Kinnate Biopharma executives and independent directors trade stock every 74 days with the average trade being worth of $2,699,377. The most recent stock trade was executed by James B. Tananbaum on 8 May 2023, trading 1,780,000 units of KNTE stock currently worth $4,984,000.
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
Kinnate Biopharma executives and other stock owners filed with the SEC include: